Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, open-label, multicenter, randomized, safety and efficacy trial of the combination of atezolizumab (Tecentriq) and sacituzumab govitecan, as a frontline treatment of patients with metastatic or inoperable locally advanced triple-negative breast cancer

Next Previous
Search
Trial Profile

A Phase Ib/II, open-label, multicenter, randomized, safety and efficacy trial of the combination of atezolizumab (Tecentriq) and sacituzumab govitecan, as a frontline treatment of patients with metastatic or inoperable locally advanced triple-negative breast cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Sacituzumab govitecan (Primary) ; Paclitaxel
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 03 Oct 2019 New trial record
    • 28 Sep 2019 According to an Immunomedics media release, this trial will be conducted under a collaboration with Roche. Trial will be a part of the MORPHEUS - a Phase 1b/2 adaptive platform to develop combinations of cancer immunotherapies rapidly. Roche will be responsible for conduct of the trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top